LTR Pharma Reports Positive SPONTAN Real-World Study Results
Key points
- 93% response rate among men seeking greater convenience and spontaneity
- 64% of post-prostatectomy patients reported improved erectile hardness and penetration
- 57% response among difficult-to-treat subgroup with prior oral ED therapy failures
Full summary
LTR Pharma Limited announced the outcomes of a real-world study of 147 men using SPONTAN®, its rapid-onset intranasal vardenafil spray. The study found a 93% response rate among men seeking greater convenience and spontaneity, 64% among post-prostatectomy patients, and 57% among those with prior oral ED therapy failures. The findings suggest SPONTAN may offer an alternative treatment option for men who do not respond well to conventional oral ED therapies. The study results will be presented at the Australian Prostate Cancer Conference and submitted for peer review.
Outlook
LTR Pharma plans to present the study data at APCC, evaluate a prospective study in the post-prostatectomy population, and implement activities ahead of ROXUS U.S. commercial availability.
Summary generated by a large language model. Please interpret with care.